We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Metrion, LifeArc Extend Collaboration to Support LifeArc's Neuroscience Drug Discovery Programme
News

Metrion, LifeArc Extend Collaboration to Support LifeArc's Neuroscience Drug Discovery Programme

Metrion, LifeArc Extend Collaboration to Support LifeArc's Neuroscience Drug Discovery Programme
News

Metrion, LifeArc Extend Collaboration to Support LifeArc's Neuroscience Drug Discovery Programme

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Metrion, LifeArc Extend Collaboration to Support LifeArc's Neuroscience Drug Discovery Programme "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy


Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, the UK medical research charity previously known as MRC Technology, newly announced an extension of their existing partnership, to support LifeArc’s neuroscience drug discovery programme.


Under the terms of the agreement Metrion will provide validated ion channel and electrophysiology-based assays and safety profiling services, and LifeArc will conduct medicinal chemistry aimed at identifying novel modulators of an undisclosed CNS ion channel target.  In addition, Metrion will contribute translational research expertise to evaluate the activity of LifeArc compounds in human neuronal networks.


Metrion will provide translational assay support by applying its extensive background knowledge in ion channel research, microelectrode array (MEA) technology, and access to its CiPA-compliant cardiac safety assays.   


Dr Andrew Southan, Chief Operating Officer, Metrion Biosciences, said: “The Metrion team has a long history of developing, validating, and providing specialist ion channel assays to optimise and select development candidate molecules.  We believe combining this with translational neuroscience and microelectrode array capability, as we are in this promising project with LifeArc, may be particularly successful in CNS research.”


Justin Bryans, Executive Director, Drug Discovery, LifeArc, commented: “LifeArc is committed to working with cutting edge organisations such as Metrion, capitalising on our combined expertise and capabilities to advance programmes addressing human health. Our previous experience in working with the team at Metrion has been excellent, and we look forward to continuing the relationship.”


This article has been republished from materials provided by Metrion Biosciences. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement